HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Innovative education, training strategies needed to address shortage of benign hematologists
• Abemaciclib fails to improve survival for patients with KRAS-positive non-small cell lung cancer
• AMA president-elect: Physicians must present ‘unified voice’ when advocating for patients, one another
• ASCO to present award to palliative care specialist
• ASH guidelines intended to fill gaps in care for individuals with sickle cell disease
• Cabozantinib extends OS in advanced hepatocellular carcinoma
• Commission harnesses ‘rare moment of unity’ to deliver cancer moonshot initiatives
• Computational biologist to lead precision medicine institute at Weill Cornell Medicine
• Huntsman Cancer Institute appoints clinical research director
• IL-12 therapy elicits encouraging response rates in melanoma
• Mike Schmidt, baseball great and melanoma survivor, promotes importance of ‘cancer game plan’
• Mount Sinai palliative care specialist receives National Academy of Medicine award
• NewYork-Presbyterian, Columbia University appoint director of cellular immunotherapy
• Pediatric nurses’ association presents awards
• The Wistar Institute president receives NCI award
• Your Cancer Game Plan helps patients proactively address communication, emotional needs
• The Lancet Oncology Commission establishes ‘practical, achievable’ cancer research priorities Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Opdivo for previously treated hepatocellular carcinoma
• FDA approves Varubi IV to prevent chemotherapy-induced nausea and vomiting
• FDA approves Verzenio for hormone receptor-positive, HER-2-negative breast cancer
• FDA grants rare pediatric disease designation to GBT440 for sickle cell disease
• Four hematology/oncology products receive breakthrough therapy designation
• PD-1/PD-L1 inhibitors stall in development for hematologic malignancies
• Seven oncology agents receive priority review
• Metastatic neuroendocrine tumor to the interatrial septum: Differentiating lipomatous hypertrophy from metastatic disease Munir Ghesani, MD, FACNM; Ana M. Franceschi, MD
• Age of transfused cells does not affect mortality rate
• Azacitidine-based combination may improve response rate in chronic myelomonocytic leukemia
• Biosimilar demonstrates similar safety, efficacy as rituximab for follicular lymphoma
• Blood test predicts resistance to androgen receptor therapy for prostate cancer
• Breast cancer outcomes for young women who choose conservative treatment improve over time
• Cancer survivors more likely to report limited access to prescriptions
• Chronic health conditions prevalent among childhood cancer survivors
• Crizotinib effectively targets ALK pathway in pediatric cancers
• Data on antithrombotic therapy for essential thrombocythemia ‘imprecise, inconsistent’
• Engineered therapy shows promise for life-threatening blood clotting disorder
• Fewer newly diagnosed patients with cancer lack insurance after ACA
• HPV testing after abnormal cytology hastens detection of cervical precancer
• Hydroxyurea appears safe for African children with sickle cell anemia
• Idarucizumab safely reverses anticoagulant effect of dabigatran
• Liver cancer remains a leading cause of cancer-related mortality worldwide
• Minimal residual disease shows significant prognostic value for multiple myeloma
• Multimodal therapy increases anaplastic thyroid cancer survival
• Hospitalization burden heavy after advanced cancer diagnosis
• Pretransplant vitamin D deficiency may heighten relapse risk in myeloid malignancies
• Provider confusion may contribute to poor HPV vaccination of childhood cancer survivors
• Reduced-intensity, standard conditioning demonstrate comparable transplant outcomes in myelodysplastic syndrome
• Regional chemotherapy prevents amputation in advanced sarcoma
• Response-based therapy intensification improves prognosis in leukemia subgroup
• Small breast cancers may be overdiagnosed because they are ‘fundamentally different’
• Venous thromboembolic events persist despite in-hospital prophylaxis
• Virus-specific T cells attack infections after hematopoietic stem cell transplantation
• White men with prostate cancer more likely to receive definitive therapy than black men
• Radiotherapy shows potential role in treatment of nodular lymphocytic Hodgkin lymphoma
• Trial assesses targeted therapies for solid tumors in children
• Addition of stereotactic ablative radiotherapy to nivolumab improves lung cancer survival
• Cancer survivor: Clinicians can help patients through emotional support, meaningful communication
• Drug-specific videos provide consistent chemotherapy education for patients
• Durvalumab extends PFS without worsening quality of life in advanced lung cancer
• Ensartinib shows promise in ALK-positive lung cancer
• Goals of care discussions capture patient-defined values in cancer care
• High mutation burden improves nivolumab efficacy for small cell lung cancer
• Ipilimumab, nivolumab shows promising control of mesothelioma
• Lenvatinib plus pembrolizumab active in metastatic clear cell renal cell carcinoma
• More support needed to minimize attrition in community-based lung cancer screening programs
• Nintedanib shows promise for malignant pleural mesothelioma
• Patients with acute myeloid leukemia often overestimate likelihood of cure
• Patients with advanced cancer prefer face-to-face consultations
• Private insurance associated with longer survival in metastatic renal cell carcinoma
• Resilience intervention improves quality of life, lowers depression in young patients with cancer
• Sitravatinib plus nivolumab demonstrates early efficacy in advanced NSCLC
• Smoking cessation appears cost-effective for lung cancer screening program
• ‘Song-cologist’ uses healing power of music to make personal connections with patients
• Treatment based on BRCA1 expression levels fails to improve non-small cell lung cancer outcomes
• Yoga therapy benefits patients with lung cancer, their caregivers
• Are malignant hematology specialists adequately prepared to care for patients with benign blood disorders?